Company intelligence / Profile preview

PaxVax

Redwood City, California, United Statesvivotif.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

PaxVax developed and commercialized specialty oral vaccines targeting infectious diseases often overlooked by larger pharmaceutical companies. Its lead product was Vaxchora®—the only FDA-approved oral cholera vaccine in the U.S.—and it also marketed Vivotif®, an oral typhoid vaccine. The company advanced several other programs through preclinical and clinical stages before being acquired by Emergent BioSolutions in August of 2018[1][2]. At the time of acquisition, it had a robust pipeline focused on travel and biodefense-related infectious diseases.

Therapeutic areas: Infectious Diseases
Modalities: Oral vaccines (live attenuated and recombinant)Viral vector-based vaccines
Industry: Biotech

Drug pipeline

2 assets

Vivotif

Commercial

Indications: Typhoid fever

1 more asset in the full pipeline.

Request access →

Partnerships

Johnson & Johnson/Janssen program acquisitionscollaborations with Swiss authorities for manufacturing expansion

Beyond the preview

Go deeper on PaxVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PaxVax.

Explore the full profile